To further evaluate the significant contribution of c-Met and TrkB coexpression in the prognosis of patients with HCC, 180 patients with HCC were divided into four groups according to the c-Met and TrkB expression levels in their tumors: c-Met high TrkB low (n = 83), c-Met high TrkB high (n = 36), c-Met low TrkB low (n = 57), and c-Met low TrkB high (n = 4). The gene discussed is NTRK2; the disease is hepatocellular carcinoma.